Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : Statement on Supply of its Single-shot COVID-19 Vaccine

06/14/2021 | 08:20am EDT

New Brunswick, N.J. - Johnson & Johnson confirms the United States Food & Drug Administration (FDA) has authorized two batches of drug substance, manufactured at the Emergent BioSolutions, Inc. Bayview facility, under the Emergency Use Authorization (EUA) for its single-shot COVID-19 vaccine.

'Since establishing our COVID-19 vaccine program, Johnson & Johnson has committed to producing safe, high-quality vaccines in order to bring health and hope to people everywhere,' said Kathy Wengel, Executive Vice President and Chief Global Supply Chain Officer, Johnson & Johnson. 'Today's decisions represent progress in our continued efforts to make a difference in this pandemic on a global scale, and we appreciate the close collaboration with the FDA and global health authorities.'

The Company continues to substantially expand its global vaccine manufacturing network as we work with regulatory and health authorities to supply our COVID-19 vaccine worldwide.

As COVID-19 continues to impact countries and cause untold suffering worldwide, our commitment has never been stronger to contribute to a global solution to this public health crisis. We believe that a single-shot, easy to distribute COVID-19 vaccine is an essential tool to combat the pandemic globally.

Cautions Concerning Forward-Looking Statements

This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding development of a potential preventive vaccine for COVID-19. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies, and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Contact:

Main Office

One Johnson & Johnson Plaza

New Brunswick

New Jersey 08933

T: (732) 524-0400

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
EMERGENT BIOSOLUTIONS INC. 0.18% 62.2 Delayed Quote.-30.76%
JOHNSON & JOHNSON -0.45% 172.525 Delayed Quote.10.15%
All news about JOHNSON & JOHNSON
11:03aJOHNSON & JOHNSON : Vaccine Tourism is Taking Off at SFO; Over 30,000 vaccines a..
AQ
08/04JOHNSON & JOHNSON : FDA - Coronavirus Update
AQ
08/04JOHNSON & JOHNSON : U.S. Govt Donates 151,200 Doses of J&J Vaccines to MoH
AQ
08/04JOHNSON & JOHNSON : 11,000 Tunisian Students Studying Abroad to Receive Covid-19..
AQ
08/03ZYMEWORKS : Says Earned Milestone Payment From Johnson & Johnson Under Licensing..
MT
08/03Johnson & Johnson Appoints Sandipan Ghatak as Head of Consumer Health India C..
CI
08/03CORONAVIRUS : AVAT to partner with UNICEF in scaling up vaccine deliveries to Af..
AQ
08/03CORONAVIRUS : AVAT to partner with UNICEF in scaling up vaccine deliveries to Af..
AQ
08/03JOHNSON & JOHNSON : Eyes Ways To Fast-Track COVID-19 Vaccine Delivery To India
MT
08/02JOHNSON & JOHNSON : Janssen Pharmaceutical - UPTRAVI Receives FDA Approval for I..
AQ
More news
Financials (USD)
Sales 2021 94 457 M - -
Net income 2021 22 808 M - -
Net Debt 2021 853 M - -
P/E ratio 2021 20,3x
Yield 2021 2,40%
Capitalization 456 B 456 B -
EV / Sales 2021 4,84x
EV / Sales 2022 4,62x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 173,36 $
Average target price 184,35 $
Spread / Average Target 6,34%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON10.15%456 367
ROCHE HOLDING AG14.56%340 460
PFIZER, INC.22.77%252 960
ELI LILLY AND COMPANY55.45%237 950
NOVARTIS AG-0.36%223 613
NOVO NORDISK A/S43.21%222 926